MX348567B - Proteina de fusion que tiene actividad de factor vii. - Google Patents
Proteina de fusion que tiene actividad de factor vii.Info
- Publication number
- MX348567B MX348567B MX2012013807A MX2012013807A MX348567B MX 348567 B MX348567 B MX 348567B MX 2012013807 A MX2012013807 A MX 2012013807A MX 2012013807 A MX2012013807 A MX 2012013807A MX 348567 B MX348567 B MX 348567B
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- factor vii
- fvii
- vii activity
- transferrin
- Prior art date
Links
- 229940012413 factor vii Drugs 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 5
- 108010023321 Factor VII Proteins 0.000 abstract 5
- 102000004338 Transferrin Human genes 0.000 abstract 2
- 108090000901 Transferrin Proteins 0.000 abstract 2
- 239000012581 transferrin Substances 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100052719 | 2010-06-04 | ||
| PCT/KR2011/004131 WO2011152694A2 (en) | 2010-06-04 | 2011-06-07 | Fusion protein having factor vii activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012013807A MX2012013807A (es) | 2012-12-17 |
| MX348567B true MX348567B (es) | 2017-06-20 |
Family
ID=45067214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013807A MX348567B (es) | 2010-06-04 | 2011-06-07 | Proteina de fusion que tiene actividad de factor vii. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9644197B2 (enExample) |
| EP (1) | EP2576625B1 (enExample) |
| JP (2) | JP6143297B2 (enExample) |
| KR (1) | KR101331101B1 (enExample) |
| CN (2) | CN107188970A (enExample) |
| AU (1) | AU2011262494B2 (enExample) |
| BR (1) | BR112012030941A2 (enExample) |
| CA (1) | CA2801223C (enExample) |
| ES (1) | ES2676874T3 (enExample) |
| MX (1) | MX348567B (enExample) |
| RU (1) | RU2585231C2 (enExample) |
| WO (1) | WO2011152694A2 (enExample) |
| ZA (1) | ZA201300066B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9644197B2 (en) | 2010-06-04 | 2017-05-09 | Sk Chemicals Co., Ltd. | Fusion protein having factor VII activity |
| MX349054B (es) * | 2010-09-28 | 2017-07-07 | Aegerion Pharmaceuticals Inc | Leptinas altamente solubles. |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014129876A1 (ko) | 2013-02-25 | 2014-08-28 | 에스케이케미칼주식회사 | 인자 vii을 포함하는 융합 단백질의 분리 및 정제 방법 |
| KR102058864B1 (ko) * | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물 |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| UA129696C2 (uk) | 2017-08-18 | 2025-07-09 | Ньютроліс Інк. | СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ |
| CN112996911A (zh) | 2018-10-08 | 2021-06-18 | 纽特雷斯股份有限公司 | 用于制造和疗法的脱氧核糖核酸酶的工程改造 |
| CN110218259B (zh) * | 2019-06-24 | 2022-09-16 | 王跃驹 | 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用 |
| CN110229237A (zh) * | 2019-06-24 | 2019-09-13 | 王跃驹 | 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| CN1628126A (zh) * | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| CN101177456A (zh) * | 2001-08-30 | 2008-05-14 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| CN100412090C (zh) * | 2002-05-01 | 2008-08-20 | 舍林股份公司 | 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白 |
| CN102268094A (zh) * | 2002-08-30 | 2011-12-07 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白抗体的融合蛋白 |
| US20070072271A1 (en) * | 2004-01-07 | 2007-03-29 | Novo Nordisk Healthcare A/G | Method for the production of recombinant proteins |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| TWI428448B (zh) * | 2006-03-24 | 2014-03-01 | Syntonix Pharmaceuticals Inc | 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５ |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| CN105727261A (zh) | 2008-06-27 | 2016-07-06 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| CN102647945B (zh) * | 2009-12-08 | 2015-07-29 | 皇家飞利浦电子股份有限公司 | 用于校正示踪剂摄取测量结果的方法和校正系统 |
| US9644197B2 (en) | 2010-06-04 | 2017-05-09 | Sk Chemicals Co., Ltd. | Fusion protein having factor VII activity |
-
2011
- 2011-06-07 US US13/701,333 patent/US9644197B2/en not_active Expired - Fee Related
- 2011-06-07 JP JP2013513120A patent/JP6143297B2/ja not_active Expired - Fee Related
- 2011-06-07 AU AU2011262494A patent/AU2011262494B2/en active Active
- 2011-06-07 CA CA2801223A patent/CA2801223C/en active Active
- 2011-06-07 CN CN201710403215.1A patent/CN107188970A/zh active Pending
- 2011-06-07 EP EP11790052.2A patent/EP2576625B1/en active Active
- 2011-06-07 RU RU2012157301/10A patent/RU2585231C2/ru active
- 2011-06-07 KR KR1020110054573A patent/KR101331101B1/ko active Active
- 2011-06-07 CN CN2011800277076A patent/CN103068854A/zh active Pending
- 2011-06-07 ES ES11790052.2T patent/ES2676874T3/es active Active
- 2011-06-07 MX MX2012013807A patent/MX348567B/es active IP Right Grant
- 2011-06-07 WO PCT/KR2011/004131 patent/WO2011152694A2/en not_active Ceased
- 2011-06-07 BR BR112012030941A patent/BR112012030941A2/pt not_active Application Discontinuation
-
2013
- 2013-01-03 ZA ZA2013/00066A patent/ZA201300066B/en unknown
-
2016
- 2016-03-25 US US15/080,757 patent/US10696960B2/en active Active
- 2016-07-01 JP JP2016131637A patent/JP6422918B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2576625A4 (en) | 2013-11-06 |
| JP6422918B2 (ja) | 2018-11-14 |
| ZA201300066B (en) | 2014-03-26 |
| MX2012013807A (es) | 2012-12-17 |
| JP2013529914A (ja) | 2013-07-25 |
| AU2011262494A1 (en) | 2013-01-24 |
| EP2576625A2 (en) | 2013-04-10 |
| AU2011262494B2 (en) | 2016-01-21 |
| ES2676874T3 (es) | 2018-07-25 |
| JP2017000144A (ja) | 2017-01-05 |
| WO2011152694A2 (en) | 2011-12-08 |
| US10696960B2 (en) | 2020-06-30 |
| US9644197B2 (en) | 2017-05-09 |
| WO2011152694A3 (en) | 2012-04-19 |
| RU2585231C2 (ru) | 2016-05-27 |
| WO2011152694A8 (en) | 2013-01-17 |
| CA2801223A1 (en) | 2011-12-08 |
| RU2012157301A (ru) | 2014-07-20 |
| EP2576625B1 (en) | 2018-04-25 |
| KR101331101B1 (ko) | 2013-11-19 |
| BR112012030941A2 (pt) | 2017-06-06 |
| KR20110133454A (ko) | 2011-12-12 |
| US20130236945A1 (en) | 2013-09-12 |
| CN103068854A (zh) | 2013-04-24 |
| CN107188970A (zh) | 2017-09-22 |
| US20160194622A1 (en) | 2016-07-07 |
| JP6143297B2 (ja) | 2017-06-07 |
| CA2801223C (en) | 2019-12-03 |
| AU2011262494A2 (en) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012013807A (es) | Proteina de fusion que tiene actividad de factor vii. | |
| MX2015001083A (es) | Polipeptidos de factor x modificados y usos de los mismos. | |
| PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
| TN2014000438A1 (en) | Anti-fcrn antibodies | |
| PH12012501658A1 (en) | Improving activity of fe-s cluster requiring proteins | |
| EP4613778A3 (en) | Anti-complement c1s antibodies and uses thereof | |
| MX363788B (es) | Métodos para la producción de polipéptidos procesados proteolíticamente. | |
| PH12013501339A1 (en) | Anti-pcsk9 antibodies and methods of use | |
| IN2012DN05237A (enExample) | ||
| MX2013008903A (es) | Metodos de desarrollo de variantes de terpeno sintasa. | |
| PT3434775T (pt) | Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| PH12016500753A1 (en) | Antibodies specific to fcrn | |
| EP4527921A3 (en) | Renal cell populations and uses thereof | |
| CA2899089C (en) | Factor ix polypeptide formulations | |
| EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
| PH12014500054A1 (en) | Formulations that stabilize proteins | |
| MX381841B (es) | Anticuerpos anti-jagged y métodos de uso. | |
| WO2012053823A3 (ko) | 인자 ix 활성을 갖는 융합 단백질 | |
| WO2013025846A3 (en) | Transferrin-tumstatin fusion protein and methods for producing and using the same | |
| WO2013059439A3 (en) | Combination therapy comprising an mmp-14 binding protein | |
| MX341733B (es) | Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular. | |
| MX2014001920A (es) | Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma. | |
| UA55856U (ru) | Способ определения биологического эффекта магнитного поля | |
| AU330741S (en) | Pendant light |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |